Nadunolimab is under clinical development by Cantargia and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Non-Small Cell Lung Cancer.

Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small ...

An immunofluorescence image of an aged mouse liver. Expression of β-galactosidase ... points to new opportunities to ...

The discovery improves the scientific understanding of cancer progression and ... in the EV-DNA to organize immune cell clusters that resist liver metastases. "This is a tumor suppressor mechanism ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell ... cancer cells more effectively. Imfinzi was first approved by the FDA in 2017 for use against various lung ...